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Skin and skin structure infections are most often caused by Grampositive bacteria such as streptococci and staphylococci. The number of these infections that are caused by methicillin-resistant Staphylococcus aureus (MRSA) has rapidly increased in recent years in both the community and hospital settings. MRSA skin infections experienced in the community can usually be effectively treated with the oral use of trimethoprim-sulfamethoxazole, clindamycin, or doxycycline. Hospitalized patients with skin and skin structure infections (e.g., cellulitis, major abscess, wound infection) caused by MRSA usually require, at least initially, intravenous treatment with an antibiotic. Vancomycin continues to be highly effective for the treatment of most patients with these infections, but a number of options are available including linezolid (Zyvox), daptomycin (Cubicin), telavancin (Vibativ), and ceftaroline (Teflaro). Linezolid is available in formulations that may be administered intravenously or orally.
In However, the clinical importance of this data has not been established.
The effectiveness of dalbavancin was demonstrated in two studies in which it was compared with a regimen of intravenous vancomycin with an option to switch to oral linezolid after 3 days. The endpoints included no increase from baseline in the lesion area, and a reduction in the lesion area of 20% or greater, at 48-72 hours after initiation of therapy. These two responses were attained in approximately 80% and 90% of patients, respectively, with both treatment regimens, and the new drug was considered to be as effective as the vancomycin regimen.
Serious hypersensitivity reactions have occurred infrequently in patients treated with dalbavancin, and its use is contraindicated in patients who have experienced such an event. Caution must be exercised in patients with a history of allergy to other glycopeptides, including vancomycin. If intravenous infusions of dalbavancin are administered rapidly, reactions that resemble "red-man syndrome" may occur (e.g., flushing of the upper body, urticaria, pruritus, rash). Slowing or stopping the infusion may be necessary for these symptoms to subside. To minimize this risk, the drug should be infused over a period of 30 minutes.
The adverse events most often reported in the clinical studies of dalbavancin include nausea (6%), headache (5%), and diarrhea (4%). Because Clostridium difficile (C. difficile)-associated diarrhea has been reported with the use of nearly all systemic antibacterial drugs including dalbavancin, this possibility should be considered in patients who experience diarrhea following use of an antibacterial agent.
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